Spots Global Cancer Trial Database for Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Official Title: A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients
Study ID: NCT02696525
Interventions
Study Description
Brief Summary: Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
Detailed Description: Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients. We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University People's Hospital, Beijing, Beijing, China
Guang Dong General Hospital, Thoracic Surgery, Guangzhou, Guangdong, China
Jiang Su Cancer Hospital, Nanjing, Jiangsu, China
Contact Details
Name: Jun Wang, M.D.
Affiliation: Peking University People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Yilong Wu, M.D.
Affiliation: Guang Dong General Hospital
Role: STUDY_CHAIR
Name: Lin Xu, M.D.
Affiliation: Jiang Su Cancer Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
